MARKET

ABIO

ABIO

Arca Biopharma Inc
NASDAQ
2.040
-0.010
-0.49%
Opening 14:52 11/29 EST
OPEN
2.030
PREV CLOSE
2.050
HIGH
2.100
LOW
2.030
VOLUME
16.85K
TURNOVER
17.81K
52 WEEK HIGH
2.600
52 WEEK LOW
1.710
MARKET CAP
29.40M
P/E (TTM)
-2.0378
1D
5D
1M
3M
1Y
5Y
One ARCA biopharma, Inc. (NASDAQ:ABIO) insider upped their stake by 5,155% in the previous year
Viewing insider transactions for ARCA biopharma, Inc.'s ( NASDAQ:ABIO ) over the last year, we see that insiders were...
Simply Wall St. · 11/14 14:24
BRIEF-Arca Biopharma Announces Third Quarter 2022 Financial Results
Reuters · 10/28 20:32
ARCA biopharma GAAP EPS of -$0.16
Seekingalpha · 10/28 20:18
ARCA biopharma Q3 EPS $(0.16) Up From $(0.33) YoY
Benzinga · 10/28 20:16
-- Earnings Flash (ABIO) ARCA BIOPHARMA Reports Q3 Loss $-0.16
-- Earnings Flash (ABIO) ARCA BIOPHARMA Reports Q3 Loss $-0.16
MT Newswires · 10/28 16:36
Wall Street Set to Open Higher as Earnings Season Accelerates, Ahead of Consumer Sentiment Survey
Wall Street Set to Open Higher as Earnings Season Accelerates, Ahead of Consumer Sentiment Survey
MT Newswires · 10/14 09:30
BRIEF-ARCA Biopharma Announces Q2 2022 Financial Results
BRIEF-ARCA Biopharma Announces Q2 2022 Financial Results
Reuters · 08/02 21:32
ARCA biopharma GAAP EPS of -$0.22
ARCA biopharma press release (NASDAQ:<a ...
Seekingalpha · 08/02 21:16
More
About ABIO
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company, which is focused on development and commercialization of targeted therapies for cardiovascular diseases. The Company's lead product includes Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201) and Gencaro (bucindolol hydrochloride). rNAPc2 (AB201) is a treatment for diseases caused by ribonucleic acid (RNA), viruses, focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus. The gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties for the treatment of atrial fibrillation (AF) in patients with heart failure. The Company is conducting Phase II b clinical trial of rNAPc2 (AB201). Its ASPEN-COVID-19 Phase IIb is a randomized, multi-center, international clinical trial evaluating two dose regimens of rNAPc2 versus heparin prescribed per local standard of care in hospitalized SARS-CoV-2 positive patients that also have an elevated D-dimer level.

Webull offers kinds of Arca Biopharma Inc stock information, including NASDAQ:ABIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABIO stock methods without spending real money on the virtual paper trading platform.